

**Returns**

As at 31 May 2022	1m %	3m %	1y %	3y %pa	5y %pa	Inception %pa (Nov13)
Castlereagh Equity	1	-3	-14	13	13	13
All Ordinaries	-3.5	2	0.7	4.7	5.3	NA
XBI	-6.8	-26	-46	-4.7	0	NA

**Portfolio Composition**

NAV per share	% in Cash	% shares in USD	% shares in AUD
1.72	51	12.5	36.5

**Commentary**

The month of May continued with similar conditions experienced in the previous 2 months. The Ukraine war drags on, lockdowns in China (with news of reopening as at the time of writing), supply chain disruptions, and rising commodities prices. The biotech sector continues to slide, reaching a 5 year low.

We continued to proceed deliberately and cautiously. During May, we were net sellers of ASX shares and redeployed a small part of the proceeds into US life sciences companies. I do not believe current conditions will give rise to a bull market continuation, especially in the biotech sector. Despite the small rebound from the lows, I have generally refrained from chasing higher prices.


As at the time of writing, news just broke of a company offering much cheaper sequencing costs. Details are scarce. but all indications point to continued price pressure in the sequencing market. Lower costs of sequencing for end users will result in increasing volumes. This is a positive tailwind for our positions in Twist Bioscience and 10X Genomics. To a lesser extent, lower input costs for sequencing will also benefit our group of industrialised drug discoverers.

I repeat what I said last month, I believe the conditions are currently favourable for deploying CE capital in a patient and methodical manner. I will continue to do so over the next several months. For any investor partners with spare capital, I believe the time is right to consider adding to your shareholding.

Thank you for your trust and confidence in us.

Regards  
**Peter Phan**


Portfolio Manager



**castlereagh**  
equity

+61 2 9283 3359 | [castlereaghequity.com.au](http://castlereaghequity.com.au) | [linkedin](#) | [twitter](#)

601/ 233 Castlereagh Street, Sydney NSW 2000, Australia



**Appendix 1: Performance**

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	XAO	XBI
2022	-5.5	0	0.5	-4.5	1								-8	-4.2	-39

XAO= All Ordinaries Index

XBI= S&P Biotech ETF

**Appendix 2: Top 5 Holdings= 32% of total portfolio**

Company
Beamtree
Smartpay
Industrialised Drug Discovery Basket
Fiducian
Suppliers of Tools Basket

\*note: holdings not ranked in any order